微创重复肝切除治疗复发性肝癌的短期手术结局
本研究回顾性分析了2005至2016年间97例因肝癌行重复肝切除的患者,筛选出68例仅行肝切除且肉眼根治的患者,其中微创组20例、开腹组48例。结果显示微创组术中出血量显著少于开腹组(159 vs. 502 ml,P=0.0035),术后住院时间显著缩短(14.2 vs. 19.2天,P=0.0275),且术后并发症仅见于开腹组(发生率19%)。研究表明对于选择性患者,微创重复肝切除可能安全有效。
要点
- 微创重复肝切除可显著减少术中出血量。
- 微创组术后住院时间显著短于开腹组。
- 术后并发症仅见于开腹组,发生率为19%。
核心结论
- 对于原发性和转移性肝癌,微创重复肝切除相比开腹重复肝切除可减少出血量和术后并发症。
- 微创重复肝切除对于选择性患者可能是可行且有效的手术方式。
研究设计与样本
- 回顾性分析2005至2016年间97例因肝癌行重复肝切除的患者,最终纳入68例接受肉眼根治性肝切除且无其他附加手术的患者。
- 微创重复肝切除组20例,开腹重复肝切除组48例,比较两组临床病理特征和手术参数。
主要发现
- 两组在性别、年龄、病毒感染状态、Child-Pugh分级、肿瘤大小、肿瘤数目、肿瘤位置及肝硬化存在方面均无统计学显著差异。
- 手术时间相似,但微创组术中出血量显著低于开腹组(159 vs. 502 ml,P=0.0035)。
- 微创组术后住院时间显著短于开腹组(14.2 vs. 19.2天,P=0.0275)。
- 术后并发症仅见于开腹组,并发症发生率为19%。
临床怎么用
- 对于选择性复发性肝癌患者,可考虑采用微创重复肝切除以减少出血和缩短住院时间。
- 需注意术后并发症的监测,尽管本研究中微创组未见并发症。
局限性
- 本研究为回顾性分析,样本量较小(共68例),可能存在选择偏倚。
- 微创组仅20例,开腹组48例,两组样本量不平衡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Repeat liver resection is an effective treatment, with long-term surgical outcomes for recurrent hepatocellular carcinoma and colorectal liver metastasis. However, the efficacy of a minimally invasive surgical approach for recurrent liver cancer is not yet confirmed. The purpose of this study is to examine the efficacy of minimally invasive repeat liver resection (MISRLR) compared with open repeat liver resection (ORLR) for primary and metastatic liver cancer. Here, we retrospectively analyzed the clinicopathological features and short-term surgical outcomes of patients undergoing MISRLR and ORLR. METHODS: From 2005 to 2016, 97 patients with liver cancer underwent repeat hepatectomy. Of these patients, 68 patients receiving macroscopically curative resection and only hepatectomy, without other additional operations, were selected. Twenty patients underwent MISRLR and 48 patients underwent ORLR. We compared the clinicopathological and surgical parameters in the MISRLR group with those in the ORLR group. RESULTS: There were no statistically significant differences in patients' gender, age, viral infection status, Child-Pugh classification, tumor size, tumor number, tumor location, or the presence of liver cirrhosis in the two groups. The operative times were similar, but blood loss was significantly lower in MISRLR group (159 vs. 502 ml, P = 0.0035). The length of the postoperative hospital stay was significantly shorter in the MISRLR group (14.2 vs. 19.2 days, P = 0.0275). Postoperative complications were observed only in the ORLR group, with a complication rate of 19%. CONCLUSIONS: We demonstrate that MISRLR for primary and metastatic liver cancer reduces blood loss and postoperative complications compared with ORLR. MISRLR might be a feasible and effective procedure for the selected patients.
引用
- Noda T, Eguchi H, Wada H, et al. Short-term surgical outcomes of minimally invasive repeat hepatectomy for recurrent liver cancer. Surg Endosc. 2017. PMID: 28639044. doi:10.1007/s00464-017-5632-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。